Dan S Kaufman研究团队设计了一种名为“NK-CAR-iPSC-NK”的细胞疗法,细胞来源是iPSC来源的NK细胞,发现不仅能有效地杀伤卵巢癌细胞,也不会产生与CAR-T类似的毒副作用。 在利用 EGFR-CAR修饰的NK-92细胞治疗胶质母细胞瘤、GD2-CAR-NK-92细胞...
性能变化:IL-18是一种多效性细胞因子,能够增强T细胞和NK细胞的增殖和IFN-γ分泌(Yasuda et al., 2019)。在小鼠模型中,IL-18分泌的CAR T细胞显示出更强的抗肿瘤活性,尤其是对大型实体瘤(Chmielewski & Abken, 2017)。表型变化:IL-18能够推动T细胞向T-bet高表达、FoxO1低表达的效应细胞表型分化,同时减少M2型...
NK92细胞系可无限增殖,对冻融敏感性较低;CAR-NK疗法比CAR-T疗法具有更好的安全性,主要表现为CAR-NK细胞的寿命短,几乎不会产生靶向效应,且由于活化的NK细胞产生的细胞因子与T细胞产生的细胞因子种类有很大不同,CAR-NK产品还有望降低CAR-T治疗中出现的CRS和神经毒性副作用;此外,CAR-NK细胞仍具有天然的抗肿瘤细胞...
The structure of a CAR-NK cell is designed to capitalize on the unique activation mechanisms of NK cells. According to research led by Dan Kaufman and colleagues, the CAR construct typically comprises an extracellular antigen recognition domain, a transmembrane domain, and an intracellular signaling ...
经过改造的T细胞是对抗一系列恶性肿瘤的有效疗法,但目前的方法依赖于自体T细胞,而自体T细胞制造困难且昂贵。要开发不被受体免疫系统排斥的强效异体T细胞,需要消除T细胞反应和自然杀伤细胞(NK)反应,这是因为这些反应通过各种机制消除外来细胞。 图片来自Nature Biotechnology, 2020, doi:10.1038/s41587-020-0601-5 ...
CAR structure for CAR T, CAR NK and CAR macrophage. CARs for CAR T, CAR NK and CAR macrophage have similar structures: the extracellular domain including the antigen binding domain and a spacer which is involved in engagement of target cells; transmembrane domain which docks CAR to immune cell...
NK92 cells and CON-NK92 cells expressed green fluorescence under a microscope,and WB results showed that CEA-CAR-NK92 cells successfully expressed the CAR structure.Compared with CON-NK92 cells and NK92 cells,CEA-CAR-NK92 cells effectively killed HT29 cells(P<0.05).CEA-CAR-NK92 cells ...
(NK) cells and the upregulation of myeloid cells expressing more antigen processing and presentation-related genes. Subsequent functional experiments confirmed that a lack of IFN-γ impaired the activation of host immune cells, which then affected the killing efficacy of CAR T-cells in vivo [85,...
NK cells: natural killer cells PI3K: phosphatidylinositol-3-kinase shRNA: short-hairpin RNA ST3GAL1: ST3 β -galactoside α -2,3-sialyltransferase 1 LFA-1: lymphocyte function-associated antigen-1 VEGF: vascular endothelial growth factor
TCR gene therapies and bispecific T-cell-engaging antibodies (BiTEs), as well as preclinical CAR natural killer (NK) cells, have also been reported to induce such toxicity11,12,13. Although a strong response was observed for CAR-T cells in patients with treatment-refractory haematologic malignanc...